Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Evaxion Biotech ( (EVAX) ) has provided an update.
On January 30, 2025, Evaxion Biotech announced the pricing of a $10.8 million public offering of American Depositary Shares and warrants, with participation from MSD Global Health Innovation Fund and other healthcare-focused investment funds. The proceeds are intended to support the advancement of Evaxion’s preclinical and clinical pipeline and cover operating expenses. This strategic move is anticipated to bolster Evaxion’s financial position, enabling further development of its innovative AI-driven vaccine solutions.
More about Evaxion Biotech
Evaxion Biotech A/S is a clinical-stage TechBio company based in Denmark, specializing in the development of AI-Immunology™ powered vaccines. The company uses its proprietary AI platform to decode the human immune system and create novel immunotherapies for cancer, bacterial, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of personalized vaccines and a preclinical pipeline for infectious diseases with significant unmet medical needs.
YTD Price Performance: -19.86%
Average Trading Volume: 1,167,386
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.13M
For an in-depth examination of EVAX stock, go to TipRanks’ Stock Analysis page.